The Future of ART Regimens for HIV Is in Long-Acting Agents
Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don’t require a daily oral pill and two-drug regimens that could decrease toxicity associated with standard triple-drug regimens. The approval of cabotegravir plus rilpivirine (Cabenuva) in January 2021 was the first to provide both benefits as a monthly ART injection. The approval was expanded to […]
Crystal Ball Cloudy for PI3K Inhibitors’ Future in Hematology
Last year, MedPage Today reported on developments leading to PI3K inhibitors losing multiple indications over safety and efficacy concerns. In this report, we outline what to expect in the coming year. The PI3K inhibitor drug class had a rough go of it in the regulatory realm during 2022. In April, participants in an unprecedented FDA […]
Year in Review: Multiple Myeloma
Developments in multiple myeloma over the past year were marked by the approvals of a first-in-class drug for relapsed or refractory disease and a second chimeric antigen receptor (CAR) T-cell therapy, as well as some encouraging news and disappointments on the research front. New Approvals Last month, the FDA granted accelerated approval to teclistamab (Tecvayli) […]
Year in Review: Lung Cancer
Lung cancer developments in 2021 were highlighted by the approval of an agent for a target once considered “undruggable,” the first approval of an adjuvant immunotherapy, broader screening recommendations from the U.S. Preventive Services Task Force (USPSTF), and more. First Approvals Targeting KRAS and a Rare EGFR Mutation In May, the FDA granted accelerated approval […]